William Richards, MD
Critical Care Medicine · Memphis, TNNPI 1932105004
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 386 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 20.9% — the pattern of someone who eats at a lot of different presentations.
Across 386 payments — averaging $15.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$815
- Boehringer Ingelheim$733
- United Therapeutics Corporation$646
- Genentech USA, Inc.$311
- Regeneron Healthcare Solutions, Inc.$292
- plus $2K from 27 others
What the payments were for
- Food & beverage$5,98099%
- Education$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 100 | $1,261 |
| AstraZeneca | 43 | $815 |
| Boehringer Ingelheim | 54 | $733 |
| United Therapeutics Corporation | 31 | $646 |
| Genentech USA, Inc. | 22 | $311 |
| Regeneron Healthcare Solutions, Inc. | 12 | $292 |
| Sanofi | 13 | $269 |
| Grifols USA, LLC | 18 | $219 |
| Mylan Specialty L.p. | 10 | $141 |
| La Jolla Pharmaceutical Company | 9 | $134 |
| Sunovion Pharmaceuticals Inc. | 10 | $122 |
| CSL Behring | 5 | $119 |
| Merck | 6 | $105 |
| Verona Pharma, Inc. | 6 | $102 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $86 |
| Harmony Biosciences LLC | 5 | $84 |
| Bayer | 5 | $78 |
| Insmed, Inc. | 3 | $75 |
| Novartis | 5 | $74 |
| Mallinckrodt Enterprises LLC | 4 | $64 |
| Tetraphase Pharmaceuticals, Inc. | 3 | $57 |
| AbbVie(2 entities) | 4 | $52 |
| Mallinckrodt Hospital Products Inc. | 2 | $33 |
| Lilly USA, LLC | 2 | $32 |
| Inogen, Inc. | 1 | $18 |
| Pfizer | 1 | $18 |
| Amgen | 1 | $17 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Advanced Respiratory, Inc | 1 | $15 |
| Viatris Specialty LLC | 1 | $14 |
| Mayne Pharma Commercial LLC | 1 | $13 |
| Gilead | 1 | $12 |
| Johnson & Johnson | 1 | $11 |
How this compares
$6,040 in reported general payments places this provider in the 80th percentile of 141 critical care medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 107 | $83,141 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 30 | $24,087 |
| Spiriva RespimatTiotropium Bromide | 31 | $18,791 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 36 | $17,589 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 30 | $17,192 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $8,790 |
| DuleraMometasone/Formoterol | 14 | $6,118 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $4,716 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 81 | $2,957 |
| Ventolin HfaAlbuterol Sulfate | 18 | $1,404 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 12 | $746 |
| Montelukast Sodium | 56 | $713 |
| Azithromycin | 16 | $217 |
| Prednisone | 64 | $179 |
| Doxycycline Hyclate | 14 | $156 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $1,261 | $109,521158 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $733 | $35,98361 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $815 | $28,80251 claims |
| MerckDulera | $105 | $6,11814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 141 critical care medicine providers in Tennessee.
Other critical care medicine in Memphis
- Anthony MattoxMemphis$33K
- Nathan WildsMemphis$19K
- Robert AguillardMemphis$11K
- Kimberly MarshMemphis$11K
- Paul DeatonMemphis$10K
- Garrettson EllisMemphis$9K
- Roy FoxMemphis$9K
- Matthew MabieMemphis$7K
- Steven WoodsMemphis$6K
- Michael MundayMemphis$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.